Evidence map›Paper›PMID 35738565›Full record

ArticleACS chemical neuroscience2022

Characterization of Pyrrolidinyl-hexahydro-pyranopiperazines as a Novel Kappa Opioid Receptor Agonist Scaffold.

Brian Reed, Michael Miller, Mayako Michino, Eduardo R Butelman, Ariel Ben-Ezra, Philip Pikus, Michelle Morochnik, Yuli Kim, Amy Ripka, Joseph Vacca and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Brian ReedLaboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, New York 10065, United States.ORCID 0000-0002-5211-366X
Michael MillerTri-Institutional Therapeutics Discovery Institute, 413 E. 69th Street, New York, New York 10021, United States.
Mayako MichinoTri-Institutional Therapeutics Discovery Institute, 413 E. 69th Street, New York, New York 10021, United States.
Eduardo R ButelmanLaboratory of the Biology of Addictive Diseases, The Rockefeller University, 1230 York Avenue, New York, New York 10065, United States.
Ariel Ben-EzraLaboratory of the Biology of Addictive Diseases, The Rockefeller University, 1230 York Avenue, New York, New York 10065, United States.
Philip PikusLaboratory of the Biology of Addictive Diseases, The Rockefeller University, 1230 York Avenue, New York, New York 10065, United States.
Michelle MorochnikLaboratory of the Biology of Addictive Diseases, The Rockefeller University, 1230 York Avenue, New York, New York 10065, United States.
Yuli KimLaboratory of the Biology of Addictive Diseases, The Rockefeller University, 1230 York Avenue, New York, New York 10065, United States.
Amy RipkaLucy Therapeutics, 501 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
Joseph VaccaJ. Vacca Consulting LLC, Telford, Pennsylvania 18969, United States.
Mary Jeanne KreekLaboratory of the Biology of Addictive Diseases, The Rockefeller University, 1230 York Avenue, New York, New York 10065, United States.
Rockefeller University · USTri-Institutional Therapeutics Discovery Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The kappa agonist structure-activity relationship around the novel, pyrrolidinyl substituted pyranopiperazine scaffold was developed. More specifically, the dichloroPhenylAcetamide-Pyrrolidinyl-PyranoPiperazine (PAPPP) core A was the focus of our work. The modulation of kappa receptor potency/G-protein activation and arrestin recruitment with respect to changes of the piperazine R group in A was demonstrated. Reduced β

Indexed as

Analgesics, OpioidReceptors, Opioid, kappaAnimalsArrestinsGTP-Binding ProteinsMiceSignal TransductionAnalgesics, OpioidArrestinsGTP-Binding ProteinsReceptors, Opioid, kappabiased agonistkappa agonistkappa receptoropioid receptor

Identifiers

PMID35738565
PMCPMC9266631
OpenAlexW4283394617

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.